Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax

Journal of Immunology

Volumn 178, Issue 1, 2007, Pages 503-510

  Liang, Xiaohong ^a   Liu, Yugang ^a   Zhang, Qiu ^a   Gao, Lifen ^a   Han, Lihui ^a   Ma, Chunhong ^a   Zhang, Lining ^a   Chen, Yonhai H ^b,c   Sun, Wensheng ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 4; HEPATITIS B VIRUS X PROTEIN; PROTEIN BAX; PROTEIN BID; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; ENZYME DEGRADATION; GENETIC TRANSFECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIZATION; TRANSGENIC MOUSE; VIRUS HEPATITIS;

EID: 33845920091     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.1.503     Document Type: Article

References (48)

1. Ksontini, R., D. B. Colagiovanni, M. D. Josephs, C. K. Edwards III, C. L. Tannahill, C. C. Solorzano, J. Norman, W. Denham, M. Clare-Salzler, S. L. MacKay, and L. L. Moldawer. 1998. Disparate roles for TNF-α and Fas ligand in concanavalin A-induced hepatitis. J. Immunol. 160: 4082-4089.
2. Ando, K., K. Hiroishi, T. Kaneko, T. Moriyama, Y. Muto, N. Kayagaki, H. Yagita, K. Okumura, and M. Imawari. 1997. Perforin, Fas/Fas ligand, and TNF-α pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J. Immunol. 158: 5283-5291.
3. Kondo, T., T. Suda, H. Fukuyama, M. Adachi, and S. Nagata. 1997. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3: 409-413.
4. Chirmule, N., A. D. Moscioni, Y. Qian, R. Qian, Y. Chen, and J. M. Wilson. 1999. Fas-Fas ligand interactions play a major role in effector functions of cytotoxic T lymphocytes after adenovirus vector-mediated gene transfer. Hum. Gene Ther. 10: 259-269.
5. Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, C. A. Smith, and R. G. Goodwin. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682.
6. Pan, G., J. Ni, Y. F. Wei, G. Yu, R. Gentz, and V. M. Dixit. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818.
7. Walczak, H., R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, et al. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5: 157-163.
8. Ashkenazi, A., R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. McMurtrey, A. Hebert, et al. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104: 155-162.
9. Mundt, B., F. Kuhnel, L. Zender, Y. Paul, H. Tillmann, C. Trautwein, M. P. Manns, and S. Kubicka. 2003. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J. 17: 94-96.
10. Zheng, S., P. Wang, G. Tsabary, and Y. H. Chen. 2004. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J. Clin. Invest. 113: 58-64.
11. Pan, G., J. Ni, G. Yu, Y. F. Wei, and V. M. Dixit. 1998. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 424: 41-45.
12. Schneider, P., J. L. Bodmer, M. Thome, K. Hofmann, N. Holler, and J. Tschopp. 1997. Characterization of two receptors for TRAIL. FEBS Lett. 416: 329-334.
13. Sheikh, M. S., T. F. Burns, Y. Huang, G. S. Wu, S. Amundson, K. S. Brooks, A. J. Fornace, Jr., and W. S. el-Deiry. 1998. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor α. Cancer Res. 58: 1593-1598.
14. Sheridan, J. P., S. A. Marsters, R. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C. L. Gray, K. Baker, W. I. Wood, et al. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821.
15. Walczak, H., M. A. Degli-Esposti, R. S. Johnson, P. J. Smolak, J. Y. Waugh, N. Boiani, M. S. Timour, M. J. Gerhart, K. A. Schooley, C. A. Smith, et al. 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16: 5386-5397.
16. Screaton, G. R., J. Mongkolsapaya, X. N. Xu, A. E. Cowper, A. J. McMichael, and J. I. Bell. 1997. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7: 693-696.
17. Kotelkin, A., E. A. Prikhod'ko, J. I. Cohen, P. L. Collins, and A. Bukreyev. 2003. Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J. Virol. 77: 9156-9172.
18. Clarke, P., S. M. Meintzer, A. C. Spalding, G. L. Johnson, and K. L. Tyler. 2001. Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene 20: 6910-6919.
19. Jeremias, I., I. Herr, T. Boehler, and K. M. Debatin. 1998. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol. 28: 143-152.
20. Hu, B., H. Zhu, S. Qiu, Y. Su, W. Ling, W. Xiao, and Y. Qi. 2004. Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins. Biochem. Biophys. Res. Commun. 325: 1153-1162.
21. Tollefson, A. E., K. Toth, K. Doronin, M. Kuppuswamy, O. A. Doronina, D. L. Lichtenstein, T. W. Hermiston, C. A. Smith, and W. S. Wold. 2001. Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J. Virol. 75: 8875-8887.
22. Kabsch, K., and A. Alonso. 2002. The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms. J. Virol. 76: 12162-12172.
23. Terradillos, O., A. de La Coste, T. Pollicino, C. Neuveut, D. Sitterlin, H. Lecoeur, M. L. Gougeon, A. Kahn, and M. A. Buendia. 2002. The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver. Oncogene 21: 377-386.
24. Janssen, H. L., H. Higuchi, A. Abdulkarim, and G. J. Gores. 2003. Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J. Hepatol. 39: 414-420.
25. Lin, N., H. Y. Chen, D. Li, S. J. Zhang, Z. X. Cheng, and X. Z. Wang. 2005. Apoptosis and its pathway in X gene-transfected HepG2 cells. World J. Gastroenterol. 11: 4326-4331.
26. Xiong, Y., Y. Jia, and H. Wang. 2000. High-level hepatitis B virus expression in transgenic mice. Infect. Dis. Info. 13: 164-165.
27. Song, K., Y. Chen, R. Goke, A. Wilmen, C. Seidel, A. Goke, B. Hilliard, and Y. Chen. 2000. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191: 1095-1104.
28. Liu, F., Y. Song, and D. Liu. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6: 1258-1266.
29. Schirmbeck, R., N. Dikopoulos, M. Kwissa, F. Leithauser, K. Lamberth, S. Buus, K. Melber, and J. Reimann. 2003. Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants. Eur. J. Immunol. 33: 3342-3352.
30. Costelli, P., P. Aoki, B. Zingaro, N. Carbo, P. Reffo, F. J. Lopez-Soriano, G. Bonelli, J. M. Argiles, and F. M. Baccino. 2003. Mice lacking TNFα receptors 1 and 2 are resistant to death and fulminant liver injury induced by agonistic anti-Fas antibody. Cell Death Differ. 10: 997-1004.
31. Yin, X. M., K. Wang, A. Gross, Y. Zhao, S. Zinkel, B. Klocke, K. A. Roth, and S. J. Korsmeyer. 1999. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400: 886-891.
32. Han, L., W. Sun, C. Ma, L. Zhang, Y. Cao, J. Song, and Y. Chen. 2002. The influence of HBV infection on TRAIL-induced apoptosis and its mechanism. Zhonghua Yi Xue Za Zhi 82: 597-600.
33. Puthalakath, H., and A. Strasser. 2002. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 9: 505-512.
34. Marsden, V. S., and A. Strasser. 2003. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annu. Rev. Immunol. 21: 71-105.
35. Coultas, L., and A. Strasser. 2003. The role of the Bcl-2 protein family in cancer. Semin. Cancer Biol. 13: 115-123.
36. Lacronique, V., A. Mignon, M. Fabre, B. Viollet, N. Rouquet, T. Molina, A. Porteu, A. Henrion, D. Bouscary, P. Varlet, et al. 1996. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med. 2: 80-86.
37. de la Coste, A., M. Fabre, N. McDonell, A. Porteu, H. Gilgenkrantz, C. Perret, A. Kahn, and A. Mignon. 1999. Differential protective effects of Bcl-xL and Bcl-2 on apoptotic liver injury in transgenic mice. Am. J. Physiol. 277: G702-G708.
38. Yin, X. M. 2000. Bid, a critical mediator for apoptosis induced by the activation of Fas/TNF-R1 death receptors in hepatocytes. J. Mol. Med. 78: 203-211.
39. Knudson, C., K. S. Tung, W. O. Tourtellotte, O. A. Brown, and S. J. Korsmeyer. 1995. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270: 96-99.
40. Chaudhary, P. M., M. Eby, A. Jasmin, A. Bookwalter, J. Murray, and L. Hood. 1997. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 7: 821-830.
41. Hu, W. H., H. Johnson, and H. B. Shu. 1999. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-κB and JNK activation and apoptosis through distinct pathways. J. Biol. Chem. 274: 30603-30610.
42. Lin, Y., A. Devin, A. Cook, M. M. Keane, M. Kelliher, S. Lipkowitz, and Z. O. Liu. 2000. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IκB kinase and c-Jun N-terminal kinase. Mol. Cell. Biol. 20: 6638-6645.
43. Harris, C. A., and E. M. Johnson, Jr. 2001. BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons. J. Biol. Chem. 276: 37754-37760.
44. Putcha, G. V., S. Le, S. Frank, C. G. Besirli, K. Clark, B. Chu, S. Alix, R. J. Youle, A. LaMarche, A. C. Maroney, and E. M. Johnson, Jr. 2003. JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron 38: 899-914.
45. Whitfield, J., S. J. Neame, L. Paquet, O. Bernard, and J. Ham. 2001. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 29: 629-643.
46. Herr, I., D. Wilhelm, E. Meyer, I. Jeremias, P. Angel, and K. M. Debatin. 1999. JNK/SAPK activity contributes to TRAIL-induced apoptosis. Cell Death Differ. 6: 130-135.
47. Muhlenbeck, F., P. Schneider, J. L. Bodmer, R. Schwenzer, A. Hauser, G. Schubert, P. Scheurich, D. Moosmayer, J. Tschopp, and H. Wajant. 2000. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J. Biol. Chem. 275: 32208-32213.
48. Ohtsuka, T., D. Buchsbaum, P. Oliver, S. Makhija, R. Kimberly, and T. Zhou. 2003. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22: 2034-2044.